These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 9484362

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Interferon beta-1b and intravenous methylprednisolone promote lesion recovery in multiple sclerosis.
    Richert ND, Ostuni JL, Bash CN, Leist TP, McFarland HF, Frank JA.
    Mult Scler; 2001 Feb; 7(1):49-58. PubMed ID: 11321194
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a.
    Gasperini C, Paolillo A, Giugni E, Galgani S, Bagnato F, Mainero C, Onesti E, Bastianello S, Pozzilli C.
    Mult Scler; 2002 Apr; 8(2):119-23. PubMed ID: 11990868
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The influence of clinical relapses and steroid therapy on the development of Gd-enhancing lesions: a longitudinal MRI study in relapsing-remitting multiple sclerosis patients.
    Gasperini C, Pozzilli C, Bastianello S, Koudriavtseva T, Colleluori A, Millefiorini E, Thompson AJ, Horsfield MA, Galgani S, Bozzao L, Fieschi C.
    Acta Neurol Scand; 1997 Apr; 95(4):201-7. PubMed ID: 9150809
    [Abstract] [Full Text] [Related]

  • 9. Interferon beta treatment for multiple sclerosis has a graduated effect on MRI enhancing lesions according to their size and pathology.
    Filippi M, Rovaris M, Capra R, Gasperini C, Prandini F, Martinelli V, Horsfield MA, Bastianello S, Sormani MP, Pozzilli C, Comi G.
    J Neurol Neurosurg Psychiatry; 1999 Sep; 67(3):386-9. PubMed ID: 10449565
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial.
    Arnold DL, Calabresi PA, Kieseier BC, Liu S, You X, Fiore D, Hung S.
    BMC Neurol; 2017 Feb 10; 17(1):29. PubMed ID: 28183276
    [Abstract] [Full Text] [Related]

  • 18. Characterization of MRI response to treatment with interferon beta-1b: contrast-enhancing MRI lesion frequency as a primary outcome measure.
    Stone LA, Frank JA, Albert PS, Bash CN, Calabresi PA, Maloni H, McFarland HF.
    Neurology; 1997 Sep 10; 49(3):862-9. PubMed ID: 9305355
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.